

## Data sheet – cycle 1 Reviewing the use of anticoagulants in patients with atrial fibrillation

Patient with atrial fibrillation	A review of patient records reveals:					Flagged for review  i.e. No tick in Box A or Box B
	A. Patient is taking a DOAC (dabigatran or rivaroxaban)	B. Patient is not taking a DOAC				
		i. Due to a documented contraindication	ii. As they do not require one, based on a review of their stroke risk, e.g. a documented CHA <sub>2</sub> DS <sub>2</sub> -VASC score within the last 12 months	iii. Due to patient preference, i.e. anticoagulation was recommended based on their current stroke risk but after an informed discussion within the last 12 months, treatment was declined	iv. As they are taking warfarin instead AND there is clinical justification, e.g. CrCl < 30mL/min, high HAS-BLED score, prosthetic heart valve, mitral stenosis, pregnancy	
1						
2						
3						
4						
5						
6						
7						
8						
9						
10						
11						
12						
13						
14						
15						
16						
17						
18						
19						
20						
21						
22						
23						
24						
25						
26						
27						
28						
29						
30						
<b>Data Summary</b>					Number of patients flagged for review target = 0%	<input style="width: 100px; height: 20px;" type="text"/>

Please retain this sheet for your records to provide evidence of participation in this audit.

## Data sheet – cycle 2 Reviewing the use of anticoagulants in patients with atrial fibrillation

Patient with atrial fibrillation	A review of patient records reveals:					Flagged for review  i.e. No tick in Box A or Box B
	A. Patient is taking a DOAC (dabigatran or rivaroxaban)	B. Patient is not taking a DOAC				
		i. Due to a documented contraindication	ii. As they do not require one, based on a review of their stroke risk, e.g. a documented CHA <sub>2</sub> DS <sub>2</sub> -VASC score within the last 12 months	iii. Due to patient preference, i.e. anticoagulation was recommended based on their current stroke risk but after an informed discussion within the last 12 months, treatment was declined	iv. As they are taking warfarin instead AND there is clinical justification, e.g. CrCl < 30mL/min, high HAS-BLED score, prosthetic heart valve, mitral stenosis, pregnancy	
1						
2						
3						
4						
5						
6						
7						
8						
9						
10						
11						
12						
13						
14						
15						
16						
17						
18						
19						
20						
21						
22						
23						
24						
25						
26						
27						
28						
29						
30						
<b>Data Summary</b>	<b>Number of patients flagged for review target = 0%</b>					<input style="width: 100px; height: 20px;" type="text"/>

Please retain this sheet for your records to provide evidence of participation in this audit.



## SUMMARY SHEET

### Audit of medical practice (CQI activity)

Topic:

Reviewing the use of anticoagulants in patients with atrial fibrillation

Date:

Activity designed by (name of organisation, if relevant):

Bpac<sup>nz</sup>

Doctor's name:

Results discussed with peer group or colleagues?

Yes

No

Date:

### FIRST CYCLE

**DATA:** Date of data collection:

**CHECK:** Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.)

**ACTION:** Describe how these improvements will be implemented.

**MONITOR:** Describe how well the process is working. When will you undertake a second cycle?

## SECOND CYCLE

**DATA:** Date of data collection:

**CHECK:** Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.)

**ACTION:** Describe how these improvements will be implemented.

**MONITOR:** Describe how well the process is working.

**COMMENTS:**